MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome-Reference-Cited by-同舟云学术

MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome

Published:2016-01-20 Issue:11 Volume:22 Page:2755-2764
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Rovira Jordina,Karube Kennosuke,Valera Alexandra,Colomer Dolors,Enjuanes Anna,Colomo Lluís,Martínez-Trillos Alejandra,Giné Eva,Dlouhy Ivan,Magnano Laura,Delgado Julio,Martínez Antonio,Villamor Neus,Campo Elías,López-Guillermo Armando

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigating the frequency of somatic MYD88 L265P mutation in primary ocular adnexal B cell lymphoma;Molecular Biology Reports;2024-09-09

2. A case report of solitary presentations of large B-cell lymphoma of immune-privileged sites (IP-LBCL) in the testis, vitreous body, and skin;Leukemia & Lymphoma;2024-07-30

3. The genomic and molecular landscape of splenic marginal zone lymphoma, biological and clinical implications;Exploration of Targeted Anti-tumor Therapy;2024-07-23

4. Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes;Targeted Oncology;2024-04-21

5. Toripalimab plus lenalidomide for central nervous system recurrence in refractory CD5+ diffuse large B-cell lymphoma with MYD88 and CD79B comutation: a case report;Translational Cancer Research;2024-02